A股異動 | 昊華科技漲停 加碼高性能防護衣生產
格隆匯2月10日丨昊華科技(600378.SH)漲停,報17.5元,總市值157億元。

昊華科技副總經理董祕劉政良上週末表示,為馳援新型冠狀病毒感染的肺炎防疫,昊華科技充分發揮軍工央企在科研和技術開發方面的優勢,旗下瀋陽橡膠研究設計院有限公司和曙光橡膠工業研究設計院火速進行技術攻關,將部分橡膠及軍用防護服產能轉產至醫用防護服生產。按照現有計劃,瀋陽院和曙光院能夠每日提供數千套的高科技醫用防護服產能,且這類防護服在消毒處理後可多次利用,將有助於緩解防護服短缺。
此外,公司旗下中昊晨光化工研究院有限公司也將加大PTFE覆膜醫用防護服原料——專用聚四氟乙烯分散樹脂的生產,確保下游生產企業的原材料供應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.